In this issue:
VESPER: Neoadjuvant ddMVAC in MIBC
LUX-Bladder 1: Afatinib in HER2-altered urothelial cancer
FIGHT-201: Pemigatinib in FGF/FGFRaltered urothelial cancer
DAD: Sacituzumab govitecan + enfortumab vedotin in urothelial cancer
THOR-2: Erdafitinib in BCG-treated, high-risk NMIBC
THOR: Erdafitinib vs. pembrolizumab in FGFR-altered urothelial cancer
Immune-related AEs & survival in urothelial cancer with atezolizumab
Outcomes in non-metastatic plasmacytoid variant of bladder cancer
Outcomes after cystectomy in bladder SqCC
Chemo-radiotherapy for high-grade cT1 urothelial cancer
Please login below to download this issue (PDF)